Skip to main content
S&P 5007,608.41+0.30%DOW52,124.66+0.06%NASDAQ26,132.65+0.58%BTC$75,390.00-2.09%ETH$2,374.30-2.74%GOLD$4,385.30+1.21%OIL$102.50-3.15%
Smart Investors Daily
CT

NASDAQ · CTSO

Cytosorbents Corp.

Healthcare · Medical - Devices

$6.06

Down-$0.44 (-7.26%)

Updated Sep 16, 2026, 5:59 PM

SID Score

6.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
45.22M
P/E ratio
-4.27
Dividend yield
0.00%
52-week range
$0.30 – $9.43
Volume
12K
Avg. volume
95.06K

Price performance

CTSO price history

1M range · 0 trading sessions · Daily adjusted prices

CTSO does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest CTSO news

The latest Smart Investors Daily articles mentioning CTSO.

Stock researchCompany · Overview

CTSO research

Overview

Company profile and research snapshot.

Company profile

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
CTSO recent ratings
DateFirmRatingTarget
Mar 26, 2026D. Boral CapitalBuy—
Jan 12, 2026D. Boral CapitalBuy—
Dec 16, 2025D. Boral CapitalBuy—
Nov 14, 2025D. Boral CapitalBuy—
Nov 14, 2025HC Wainwright & Co.Neutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Princeton, New Jersey--(Newsfile Corp. - September 4, 2026) - CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, is pleased to announce its participation at the upcoming Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9-10, 2026, in New York City. Dr. Phillip Chan, CEO and Peter Mariani, CFO will be attending the conference,...

Yahoo · Sep 3, 2026

CytoSorbents Announces Reverse Stock Split

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it will effect a one-for-twenty (1:20) reverse stock split (the "Reverse Stock Split") of its common stock, par value $0.001 per share (the "Common Stock"). The Reverse Stock Split is expected to become effective on September 8, 2026, Eastern Time (the "Effective Time"), and the Common Stock is expected to

Yahoo · Sep 3, 2026

CTSO: CytoSorbents Announces Very Positive New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor

By Tom Kerr, CFA NASDAQ: CTSO READ THE FULL CTSO RESEARCH REPORT New Findings Presented at European Society of Cardiology (ESC) Congress 2026 On September 2, 2026, the CytoSorbents (NASDAQ: CTSO) announced an independent new patient-level matched analysis of real-world data demonstrating that intraoperative use of CytoSorb was associated with a significant reduction in severe perioperative

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By